A Phase 2 interventional study of VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI) and Fludarabine in Acute Myeloid Leukemia, Myeloproliferative Neoplasm and Myelodysplastic Syndromes, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Stanford University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies testing fludarabine in Leukemia, Myeloid, Acute — 34 open to participants now, 49 under way, 4 of them phase 3. fludarabine · Leukemia, Myeloid, Acute.
Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, this one is the 119th largest by planned enrollment of the 188 interventional ones that give a count, is one of 10 that started in 2026, is one of 96 in phase 2, reaches primary completion later than 28 of the 48 other live ones, and was the 190th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →34 of the 191 studies testing fludarabine in Leukemia, Myeloid, Acute are open now, in 4 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 2–75
Roswell Park Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 127 · Phase 3 13 · Phase 4 3
First in 1996; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 47 across the 188 interventional studies. Of the 129 that completed or were terminated, 75 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 191 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,170 studies on the registry; 431 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
19 studies in Leukemia, Myeloid, Acute by Stanford University: 5 open now, 5 under way, none of them phase 3. Of 12 finished, 6 (50%) have results posted.
Among the 19 studies in Leukemia, Myeloid, Acute by Stanford University, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 2, and was the 19th registered.
Stanford University’s Leukemia, Myeloid, Acute studies by the year they started, since 1995.
14 of the studies testing fludarabine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03121014University of Illinois at ChicagoStudy of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes | 2026-11 |
| NCT02143830Children's Hospital Medical Center, CincinnatiHSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | 2026-12 |
| NCT04644016Memorial Sloan Kettering Cancer CenterCord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | 2026-12-20 |
| NCT04375631Fred Hutchinson Cancer CenterCLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | 2027-02-28 |
| NCT04872595Memorial Sloan Kettering Cancer CenterA Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, from their registry updates:
Among Stanford University’s 19 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity. Total marrow and lymphoid irradiation (TMLI) is a specialized radiation technique that specifically targets marrow and lymphoid tissue to maximize antitumor efficacy while reducing off target toxicity. Despite these benefits, TMLI is technically challenging and time consuming. The radiation oncology team at Stanford has developed an automated TMLI platform to overcome these challenges. In this phase II trial, automation will be incorporated into a previously validated conditioning regimen of fludarabine/cyclophosphamide/TMLI HCT with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis to confirm the feasibility and safety of automation in patients receiving allogeneic HCT for high-risk myeloid malignancies.
Inclusion Criteria for 20 Gy Arm (Cohort A)
Age, Performance Status, and Graft Criteria require all of the following bullet points:
Eligible Diseases (Any one of the following)
Acute Myeloid Leukemia (AML) Must have at least one of the following characteristics:
Myelodysplastic syndrome Must have at least one of the following characteristics at the time of conditioning:
Myeloproliferative neoplasms (MPN) or MDS/MPN overlap. Must have at least one of the following characteristics:
Adequate organ function is defined as all of the following:
Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and > 45% confirmed by MUGA or echocardiography Pulmonary: DLCO, , FVC > 50% predicted, and absence of O2 requirements. Liver: Transaminases \< 3 x (ULN) and total ≤ 2 mg/dL except for patients with Gilbert's syndrome or hemolysis (as indicated by provider documentation).
Renal: Creatinine \< 2.0 mg/dL (adults) and > 40 mL/min.
Inclusion Criteria for 12 Gy Arm (Cohort B)
Age, Performance Status, and Graft Criteria require all of the following bullet points:
Age 18 to 70 years (inclusive) Adequate performance status is defined as Karnofsky score ≥ 70% Patients must be receiving an allogeneic peripheral blood stem cell graft Patients and selected donor must be HLA typed at high resolution using DNA based typing at the following HLA-loci: HLA-A, -B, -C and DRB1. Donors may be an 8/8 matched sibling donor, 8/8 matched unrelated donor, haploidentical related donor, or 7/8 mismatched unrelated donor.
Adequate organ function is defined as all of the following:
Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40% confirmed by MUGA or echocardiography Pulmonary: DLCO, FEV1, FVC > 40% predicted, and absence of O2 requirements. Liver: Transaminases \< 3 x upper limit of normal (ULN) and total bilirubin ≤ 2 mg/dL except for patients with Gilbert's syndrome or hemolysis (as indicated by provider documentation).
Renal: Creatinine \< 2.0 mg/dL (adults) and creatinine clearance > 40 mL/min. Sexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive fludarabine, cyclophosphamide, and TMLI 200 cGy BID conditioning followed by allogeneic peripheral blood stem cell transplantation (PBSCT). Post-transplant GVHD prophylaxis includes cyclophosphamide, mycophenolate mofetil, and tacrolimus.
Radiation: VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI) · Drug: Fludarabine · Drug: Cyclophosphamide · Biological: Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) · Drug: Mycophenolate mofetil (MMF) · Drug: Tacrolimus
Participants receive fludarabine, cyclophosphamide, and TMLI 150 cGy BID conditioning followed by allogeneic peripheral blood stem cell transplantation (PBSCT). Post-transplant GVHD prophylaxis includes cyclophosphamide, mycophenolate mofetil, and tacrolimus.
Radiation: VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI) · Drug: Fludarabine · Drug: Cyclophosphamide · Biological: Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) · Drug: Mycophenolate mofetil (MMF) · Drug: Tacrolimus
Patients receive VMAT-based TMLI with daily image-guided radiation therapy (IGRT) for treatment localization and verification prior to radiation delivery.
Fludarabine 25 mg/m² IV administered daily on Days -7 through -3.
Cyclophosphamide 14.5 mg/kg IV on Days -7 and -6 as part of conditioning and 50 mg/kg IV on Days +3 and +4 as post-transplant GVHD prophylaxis.
Allogeneic peripheral blood stem cell transplantation administered on Day 0.
Mycophenolate mofetil initiated on Day +5 and continued through Day +35 for GVHD prophylaxis.
Mycophenolate mofetil initiated on Day +5 and continued through Day +35 for GVHD prophylaxis.
Non-Relapse Mortality (NRM)
Death without prior disease relapse following allogeneic peripheral blood stem cell transplantation.
Time frame: Day 100 after transplantation
Neutrophil Engraftment
Neutrophil engraftment following allogeneic peripheral blood stem cell transplantation.
Time frame: Through Day 100 after transplantation
Risk of Relapse
Disease relapse following allogeneic peripheral blood stem cell transplantation.
Time frame: Day 100 post-transplant
Disease-Free Survival (DFS)
Disease-free survival following allogeneic peripheral blood stem cell transplantation.
Time frame: Day 100 post-transplant
Overall Survival (OS)
Overall survival following allogeneic peripheral blood stem cell transplantation.
Time frame: Day 100 post-transplant
Incidence of Grade II-IV Acute Graft-versus-Host Disease (GVHD)
Incidence and severity of Grade II-IV acute graft-versus-host disease following allogeneic peripheral blood stem cell transplantation.
Time frame: Day 100 post-transplant
Incidence of Grade III-IV Acute Graft-versus-Host Disease (GVHD)
Incidence and severity of Grade III-IV acute graft-versus-host disease following allogeneic peripheral blood stem cell transplantation.
Time frame: Day 100 post-transplant
Bearman Regimen-Related Toxicity
Regimen-related toxicity assessed using the Bearman Toxicity Scale. Toxicity will be evaluated by organ system and graded according to severity (Grades I-IV).
Time frame: Day 100 post-transplant
Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.
Of 386 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 21 months is below that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Sep 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fludarabine · Cyclophosphamide · Mycophenolic Acid · Tacrolimus